Latest News

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity / image credit Steven J Nicholls, MBBS, PhD, Monash University Melbourne, Australia
Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

November 5th 2024

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose / image credit: ©New Africa/AdobeStock
Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose

November 1st 2024

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys:  ©krishnacreations/stock.adobe.com
Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

October 21st 2024

Why Are Women Still Missing from Cardiovascular Clinical Trials? image credit ©Chinnapong/stock.adobe.com
Why Are Women Still Missing from Cardiovascular Clinical Trials?

October 17th 2024

COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types
COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types

October 9th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.